iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics - The Lancet Oncology
Assessing Immunotherapy Response and Progression
The Radiology Assistant : RECIST 1.1 - and more
CDISC Compliant Implementation of iRECIST and LYRIC for Immunomodulatory Therapy Trials
Criteria of Assessment with Imaging iRECIST, irRECIST, irRC, RECIST1.1
Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis | Journal for ImmunoTherapy of Cancer
Kaplan-Meier curves of OS and PFS based on iRECIST to compare outcomes... | Download Scientific Diagram
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. - Abstract - Europe PMC
iRECIST: how to do it | Cancer Imaging | Full Text
CDISC Compliant Implementation of iRECIST and LYRIC for Immunomodulatory Therapy Trials
EPOS™
Novel oncologic therapy response criteria (iRECIST and more) - Mint Medical GmbH
Novel oncologic therapy response criteria (iRECIST and more) - Mint Medical GmbH
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics - The Lancet Oncology
iRECIST Overview
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics - The Lancet Oncology
Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis | Journal for ImmunoTherapy of Cancer
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. - Abstract - Europe PMC
iRECIST Overview
Response Criteria in Oncologic Imaging: Review of Traditional and New Criteria | RadioGraphics
Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis | Journal for ImmunoTherapy of Cancer
PDF) Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis
iRECIST: how to do it | Cancer Imaging | Full Text
